---
layout: default
title: Ponatinib
parent: 僅模型預測 (L5)
nav_order: 312
evidence_level: L5
indication_count: 2
---

# Ponatinib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **2** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# PONATINIB: From Unspecified Indication to Fibromatosis, Gingival

## One-Sentence Summary

> No approved-indication or mechanism-of-action data for PONATINIB is currently available in this evidence pack.
> The TxGNN model predicts potential efficacy for **Fibromatosis, Gingival**,
> but **no clinical trials and no publications** currently support this direction.

---

## Quick Overview

| Item | Content |
|------|------|
| Predicted New Indication | Fibromatosis, Gingival |
| TxGNN Prediction Score | 99.04% |
| Evidence Level | L5 |
| Germany Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

*Original Indication is omitted — no `approved_indication_text` or `original_indications` data is present in the evidence pack.*

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for PONATINIB, and no original/approved indication is recorded in this evidence pack. As a result, no mechanistic rationale linking a known original indication to the predicted new indication (Fibromatosis, Gingival) can be constructed at this time.

This prediction is based solely on the TxGNN knowledge-graph model's pattern score (99.04%, global rank 9776), without corroborating clinical trial or literature evidence. It should be treated as a hypothesis-generating signal only, pending mechanistic and regulatory data retrieval (see `data_gaps` DG001, DG002).

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Germany Market Information

No marketing authorizations are currently registered (`market_status: 未上市`, `total_licenses: 0`).

---

## Safety Considerations

Please refer to the package insert for safety information.

*Note: TFDA/label warnings and contraindications are flagged as a **Blocking** data gap (DG001) — this drug cannot proceed past initial safety screening (S1) until label data is retrieved.*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The predicted indication has no supporting clinical trial or literature evidence (L5), and a Blocking data gap (missing TFDA warnings/contraindications) prevents any safety pre-screening. The drug is also not currently marketed in this jurisdiction.

**To proceed, the following is needed:**
- Retrieve TFDA/label warnings and contraindications (DG001, Blocking)
- Retrieve mechanism of action data from DrugBank (DG002, High)
- Retrieve original approved indication(s) for PONATINIB to establish a mechanistic rationale
- Search for preclinical or case-level evidence specifically linking PONATINIB to gingival fibromatosis
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

